Intercept Pharmaceuticals Inc., is a clinical stage biopharmaceutical company developing therapeutics for the treatment of chronic fibrotic and metabolic diseases.
Current News
  • January 25, 2010 - Intercept Pharmaceuticals Raises $25 Million Series B Financing, Dr. Lorenzo Tallarigo Appointed Chairman More »


  • October 27, 2009 - Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for
    Primary Biliary Cirrhosis More »


  • October 2, 2009 - Intercept Pharmaceuticals' FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease More »


  • September 2, 2009 - Cell Metabolism Publishes Novel TGR5-Mediated Mechanism for the Treatment of Diabetes and Obesity ... More »


  • August 7th, 2008 - Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling ... More »
Upcoming Events
  • April 15, 2010 - Dr. David Shapiro, Intercept's CMO, will present an abstract entitled: Farnesoid-X Receptor Agonists: a New Class of Drugs for the Treatment of PBC? An International Study Evaluating the Addition of INT-747 to Ursodeoxycholic Acid" at the International Liver CongressTM 2010 by EASL, taking place in Vienna, Austria, April 14-18, 2010 on Thursday, April 15, 2010 at 14:30-16:30 local time.


  • April 14-18, 2010 - Poster presentation by Giovanni Rizzo, "Functional characterization of the semi-synthetic bile acid derivative INT-767, a dual FXR and TGR5 agonist" at the International Liver CongressTM 2010 by EASL, taking place in Vienna, Austria, April 14-18, 2010.